Home ›
Trademark Categories ›
Pharmaceuticals ›
2021 ›
YO ›
YORDOVI
Trademark search for:
YORDOVI
No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.
Trademark records may change over time.
For the most up-to-date trademark status, domain availability,
and social handle checks, run a live search.
Check latest trademark, domains & social handles
Live search · Most up-to-date results
USPTO Filing History
Key events recorded for this trademark application
2021-12-10 — Application filed
2022-01-12 — Application filed
2022-09-19 — Assigned to examiner
2022-09-20 — Examiners amendment and/or priority action - completed
2022-09-20 — Notification of examiner's amendment/priority action e-mailed
2022-09-20 — Examiner's amendment/priority action e-mailed
2022-09-20 — Combined examiner's amendment/priority action automatic entry
2023-03-03 — Office action issued
2023-06-29 — Teas/email correspondence entered
2023-06-29 — Assigned to lie
2023-06-29 — Correspondence received in law office
2023-07-07 — Approved for pub - principal register
2023-07-26 — Notification of notice of publication e-mailed
2023-08-15 — Published for opposition
2023-08-15 — Official gazette publication confirmation e-mailed
2023-10-10 — Noa e-mailed - sou required from applicant
2024-03-28 — Sou teas extension received
2024-03-28 — Sou extension 1 filed
2024-03-28 — Sou extension 1 granted
2024-03-29 — Notice of approval of extension request e-mailed
2024-11-11 — Application abandoned
2024-11-11 — Application abandoned
2024-11-11 — Final status recorded
Owner Information
Allarity Therapeutics, Inc.
Cambridge , MA
Allarity Therapeutics, Inc.
Cambridge , MA
Correspondent
Richard Todd Armstrong CLARK+ELBING LLP 101 FEDERAL STREET, 15TH FLOOR BOSTON, MA 02110 United States
Filing Details
Filing Date:
2021-12-10
Status Date:
2024-11-11
Disclaimer: This page is informational only and does not constitute legal advice.
Trademark availability depends on jurisdiction, usage, and legal interpretation.